Dashboard
Manage Tickers

GFORNKGen Biotech, Inc.

Nasdaq nkgenbiotech.com


$ 1.60 $ 0.10 (6.67 %)    

Wednesday, 29-May-2024 14:40:42 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 1.30 (0.29 %)
DIA $ 398.57 $ -0.38 (-0.1 %)
SPY $ 530.36 $ 0.79 (0.15 %)
TLT $ 91.26 $ -0.42 (-0.48 %)
GLD $ 225.37 $ 0.26 (0.12 %)
$ 1.5
$ 1.49
$ 0.00 x 0
$ 1.60 x 100
$ 1.49 - $ 1.60
$ 0.78 - $ 12.88
187,198
na
32.9M
$ -0.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-20-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/28/2023 18:32:08

  During Thursday's session, 406 companies made new 52-week lows.

nkgen-biotech-announces-first-patient-dosed-in-phase-i-clinical-trial-of-snk02-allogeneic-nk-cell-therapy-product-candidate-for-the-treatment-of-solid-tumors
NKGen Biotech Announces First Patient Dose...
08/24/2023 12:11:50

graf-acquisition-iv-nkgen-biotech-announce-letter-of-intent-for-business-combination
Graf Acquisition IV, NKGen Biotech Announc...
03/23/2023 21:52:35

Core News & Articles
Graf Acquisition Corp. IV Shares Open For ...
05/21/2021 15:14:25

graf-acquisition-corp-iv-shares-expected-to-open-for-trade-today-ipo-priced-10unit
Graf Acquisition Corp. IV Shares Expected ...
05/21/2021 13:25:39

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION